GleamWall
中文EN

SERA SERA PROGNOSTICS, INC.

Services-Medical Laboratories · Nasdaq · SEC CIK 1534969 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.1%
TTM net income YoY-2.6%
TTM EPS YoY11.8%
Revenue 3-yr CAGR-33.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-38,755.2%
Net margin-34,866.7%
FCF margin-30,199.0%
EBITDA margin-37,922.9%

Returns

ROE-49.7%
ROA-35.6%
ROIC (approx.)-46.5%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets34.4%
Debt / equity0.00x
Current ratio1.88x
Interest coverage-5,315.00x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue508.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$42,000$30,000$14,000$10,000$16,000$17,000$38,000$24,000
Cost of revenue—$50,000$42,000$42,000$41,000$41,000$40,000$32,000
Gross profit—-$20,000-$28,000-$32,000-$25,000-$24,000-$2,000-$8,000
R&D expense$2.72M$3.49M$3.03M$3.22M$3.28M$3.34M$3.33M$3.14M
SG&A expense$3.89M$4.25M$4.29M$4.04M$4.08M$4.14M$4.44M$4.01M
Operating income-$8.89M-$10.00M-$9.36M-$8.95M-$8.98M-$9.32M-$9.25M-$9.42M
Interest expense$2,000$2,000$2,000$1,000$2,000$2,000$4,000$6,000
Net income-$8.05M-$9.14M-$8.40M-$7.88M-$7.81M-$8.05M-$8.19M-$8.58M
EBITDA-$8.69M-$9.84M-$9.17M-$8.71M-$8.78M-$9.11M-$9.03M-$9.21M
EPS (basic)-0.16-0.18-0.17—-0.16-0.16-0.20—
EPS (diluted)-0.16-0.18-0.17—-0.16-0.16-0.20—
Weighted avg. shares (diluted)50.79M50.48M50.26M—49.53M49.07M41.97M—
Balance sheet
Cash & equivalents$3.99M$4.40M$4.17M$3.94M$4.08M$5.02M$5.23M$4.04M
Short-term investments$40.10M$42.05M$43.23M$35.26M$39.22M$35.14M$40.97M$42.19M
Receivables$17,000$10,000$11,000$12,000$14,000$17,000$25,000$34,000
Current assets$46.22M$48.13M$49.73M$40.77M$44.49M$40.87M$47.28M$47.60M
PP&E, net$1.72M$1.42M$1.10M$1.15M$1.03M$1.20M$1.31M$1.24M
Intangibles$859,000$888,000$881,000$910,000$939,000$968,000$997,000$1.03M
Total assets$79.98M$86.74M$93.54M$101.93M$108.12M$111.83M$118.18M$72.58M
Current liabilities$24.53M$24.36M$23.42M$24.19M$23.50M$23.60M$23.40M$24.77M
Total liabilities$27.54M$27.36M$25.92M$26.52M$25.94M$23.60M$23.40M$24.77M
Shareholders' equity$52.44M$59.38M$67.62M$75.41M$82.18M$88.23M$94.78M$47.80M
Cash flow statement
Operating cash flow-$7.30M-$6.31M-$8.77M-$6.12M-$6.48M-$5.47M-$7.55M-$6.26M
Capital expenditure$134,000$16,000$8,000$330,000$112,000$281,000$3,000$8,000
Free cash flow-$7.43M-$6.33M-$8.78M-$6.45M-$6.59M-$5.75M-$7.56M-$6.27M
Investing cash flow$6.84M$6.39M$8.98M$5.89M$5.17M$5.24M-$44.80M$7.38M
Financing cash flow$48,000$140,000$20,000$93,000$373,000$18,000$53.54M$234,000
Depreciation & amortization$200,000$162,000$193,000$244,000$200,000$208,000$216,000$211,000
Stock-based compensation$1.28M$823,000$835,000$1.02M$1.25M$1.34M$1.49M$1.62M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.